Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Microencapsulated CYP 2B1-expressing cells - PharmaCyte Biotech

Drug Profile

Microencapsulated CYP 2B1-expressing cells - PharmaCyte Biotech

Alternative Names: Breast cancer cell therapy - PharmaCyte Biotech; CYP-2B1-gene-therapy-PharmaCyte-Biotech; CypCaps; Cytochrome-P450-2B1-gene-therapy-PharmaCyte-Biotech; Encapsulated cyclophosphamide-activating cells - PharmaCyte Biotech; Encapsulated ifosfamide-activating cells - PharmaCyte Biotech; Encapsulated-cell-therapy-PharmaCyte-Biotech; Microencapsulated-P450-2B1-expressing-cells-PharmaCyte-Biotech; NovaCaps®; Ovarian cancer cell therapy - PharmaCyte Biotech; P450-2B1-gene-therapy-PharmaCyte-Biotech; Pancreatic cancer cell therapy - PharmaCyte Biotech

Latest Information Update: 09 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Austrianova; SG Austria
  • Developer PharmaCyte Biotech; Translational Drug Development
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cytochrome P-450 enzyme system stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Breast cancer; Malignant ascites; Ovarian cancer
  • Research Pain

Most Recent Events

  • 05 Apr 2018 PharmaCyte Biotech plans a clinical trial for Pancreatic cancer (Late-stage disease, Inoperable/Unresectable)
  • 26 Mar 2018 PharmaCyte Biotech files a patent protection with the United States Patent and Trademark Office for microencapsulated CYP 2B1-expressing cells
  • 06 Feb 2018 PharmaCyte plans to file an IND application with the US FDA in USA in second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top